Hubli Diagnostics Medicare And Research Centre Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-05-2024
- Paid Up Capital ₹ 0.74 M
as on 20-05-2024
- Company Age 26 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 25.23%
(FY 2022)
- Profit 121.07%
(FY 2022)
- Ebitda 361.94%
(FY 2022)
- Net Worth 4.15%
(FY 2022)
- Total Assets -6.99%
(FY 2022)
About Hubli Diagnostics Medicare And Research Centre
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.74 M, as per Ministry of Corporate Affairs (MCA) records.
Arvind Yelamali, Renuka Dugani, and Laxmi Yenni serve as directors at the Company.
- CIN/LLPIN
U29219KA1998PTC023935
- Company No.
023935
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jul 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Dharwad, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hubli Diagnostics Medicare And Research Centre?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvind Yelamali  | Director | 08-Jul-1998 | Current |
| Renuka Dugani | Director | 15-Jul-1998 | Current |
| Laxmi Yenni | Director | 08-Jul-1998 | Current |
Financial Performance of Hubli Diagnostics Medicare And Research Centre.
Hubli Diagnostics Medicare And Research Centre Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25.23% increase. The company also saw a substantial improvement in profitability, with a 121.07% increase in profit. The company's net worth moved up by a moderate rise of 4.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hubli Diagnostics Medicare And Research Centre?
In 2017, Hubli Diagnostics Medicare And Research Centre had a promoter holding of 40.49% and a public holding of 59.51%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jeeom Bio-Subjective Research Lab And Productions Private LimitedActive 2 years 3 monthsLaxmi Yenni is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hubli Diagnostics Medicare And Research Centre?
Unlock and access historical data on people associated with Hubli Diagnostics Medicare And Research Centre, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hubli Diagnostics Medicare And Research Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hubli Diagnostics Medicare And Research Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
